Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 5
Treatment-assignment count: 0
Stratification count: 0
Trial Selection Rising
ALK fusion
gastric cancer · Combination Therapy
ALK fusion is flagged as trial selection rising because public trials show inclusion required evidence in 7 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 5
Common snippets: MSI-H | MSI-H | MSI-H
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Manual Review Required
CDx maturity score: 2/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT07385703 | https://clinicaltrials.gov/study/NCT05769725 | https://clinicaltrials.gov/study/NCT04603040 | https://clinicaltrials.gov/study/NCT04152889 | https://clinicaltrials.gov/study/NCT05713838 | https://clinicaltrials.gov/study/NCT03504397 | https://clinicaltrials.gov/study/NCT03653507